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Abstract
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-
acetylgalactosamine-6-sulfatase (GALNS), an enzyme that degrades keratan sulfate (KS). Currently no therapy for MPS IVA is
available. We produced recombinant human (rh)GALNS as a potential enzyme replacement therapy for MPS IVA. Chinese
hamster ovary cells stably overexpressing GALNS and sulfatase modifying factor-1 were used to produce active (,2 U/mg)
and pure ($97%) rhGALNS. The recombinant enzyme was phosphorylated and was dose-dependently taken up by
mannose-6-phosphate receptor (Kuptake=2.5 nM), thereby restoring enzyme activity in MPS IVA fibroblasts. In the absence
of an animal model with a skeletal phenotype, we established chondrocytes isolated from two MPS IVA patients as a disease
model in vitro. MPS IVA chondrocyte GALNS activity was not detectable and the cells exhibited KS storage up to 11-fold
higher than unaffected chondrocytes. MPS IVA chondrocytes internalized rhGALNS into lysosomes, resulting in
normalization of enzyme activity and decrease in KS storage. rhGALNS treatment also modulated gene expression,
increasing expression of chondrogenic genes Collagen II, Collagen X, Aggrecan and Sox9 and decreasing abnormal
expression of Collagen I. Intravenous administration of rhGALNS resulted in biodistribution throughout all layers of the heart
valve and the entire thickness of the growth plate in wild-type mice. We show that enzyme replacement therapy with
recombinant human GALNS results in clearance of keratan sulfate accumulation, and that such treatment ameliorates
aberrant gene expression in human chondrocytes in vitro. Penetration of the therapeutic enzyme throughout poorly
vascularized, but clinically relevant tissues, including growth plate cartilage and heart valve, as well as macrophages and
hepatocytes in wild-type mouse, further supports development of rhGALNS as enzyme replacement therapy for MPS IVA.
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Introduction
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome;
OMIM #253000), is an autosomal recessive disorder caused by
deficiency of N-acetylgalactosamine-6-sulfatase (GALNS) [1]. This
enzyme hydrolyses sulfate ester bonds and is required during the
sequential degradation of the glycosaminoglycans keratan sulfate
(KS) and chondroitin-6-sulfate in the lysosomes [2]. Deficiency in
GALNS leads to lysosomal accumulation of glycosaminoglycans
and subsequent cellular pathology, most notably in connective
tissues rich in KS, including cartilage, cornea and heart valve
[1,3]. A number of other cell types, including macrophages [4,5]
and coronary intimal smooth muscle cells [5] also contain
lysosomal storage, suggesting that the pathophysiology of MPS
IVA may extend beyond the KS-rich tissues. Interestingly, growth
plate KS does not accumulate in mouse, in the absence of
GALNS, rendering the mouse models inappropriate [6].
Like other MPS disorders, MPS IVA is clinically heterogeneous,
ranging from severe skeletal dysplasia with early mortality to
milder forms [7]. The skeletal dysplasia is particularly evident in
epiphyseal growth plates and vertebrae, and is hallmarked by
spondyloepiphyseal dysplasia with genu valga, pectus carinatum,
spinal kyphosis and odontoid hypoplasia. Thoracic cage deformity
contributes to severe respiratory restriction and potentially
pulmonary failure. Odontoid hypoplasia is frequent and, along
with ligamentous laxity, often results in cervical instability and
high cervical spinal cord compression [8]. Degeneration of
articular cartilage leads to early-onset osteoarthritis. Corneal
clouding as well as aortic and mitral valve pathology secondary to
stenosis are also observed [9]. Unlike most MPS diseases, MPS
IVA is not characterized by impairment of mental status.
Growth plate chondrocyte pathology in MPS IVA is charac-
terized by vacuolar distention, defective differentiation, chaotic
arrangement and poorly calcified matrix [10,11]. On the contrary,
bone cells, osteoblasts and osteoclasts, appear unaffected
[10,11,12], although vacuolar distention has been observed in
osteocytes [13]. Histological studies confirm that although the
bone tissue from MPS IVA patients is reduced in quantity, at the
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12194histological and ultrastructural level it is qualitatively comparable
to unaffected bone [11,14]. Anderson et al concludes that the cause
of dwarfism lies primarily in the deficit in chondrocyte
differentiation, rather than abnormal bone formation [10].
Articular cartilage chondrocytes are also vacuolated, disorganized,
and exhibit an altered expression of extracellular matrix
components [15], changes that may be associated with early-onset
osteoarthritis observed in MPS IVA [14]. Cartilage and heart
valve spongiosa, the major therapeutic target tissues in MPS IVA,
are largely avascular [16,17], and are as such challenging to
penetrate with therapeutic compounds.
Treatment options for children with MPS IVA are limited to
bone marrow transplantation and frequent orthopedic surgeries.
Patients show incomplete response to bone marrow transplanta-
tion, which is furthermore associated with high morbidity and
mortality [18]. The advent of enzyme replacement therapy (ERT)
brought significant improvement in the management of lysosomal
storage diseases, including MPS I, II, and VI, Gaucher disease,
Fabry disease and Pompe disease [19]. We here report production
and characterization of recombinant human GALNS (rhGALNS)
for potential enzyme replacement therapy of MPS IVA. We
furthermore describe establishment of a novel model of disease,
primary human MPS IVA chondrocytes in vitro. In this model we
show rhGALNS uptake by lysosomes, subsequent clearance of KS
storage and changes in cellular function, in terms of gene
expression. Finally, we address the issue of rhGALNS delivery to
clinically relevant tissues, and show, for the first time, penetration
of the therapeutic enzyme throughout the growth plate, all layers
of the heart valve as well as liver macrophages in wild-type mice.
Results and Discussion
Production, purification and characterization of rhGALNS
We produced rhGALNS from conditioned media from CHO
cells stably overexpressing GALNS and sulfatase modifying factor
1 (SUMF1). SUMF1 encodes the formylglycine-generating
enzyme required for activation of all sulfatases including those
associated with the mucopolysaccharidoses [20,21,22]. The overall
purification recovery of rhGALNS was ,56% with typical specific
enzyme activity of 2 U/mg. The enzyme was $97% pure based
on reverse-phase HPLC. Figure 1A shows SDS-PAGE of the
purified enzyme, with a major species of ,55 kDa, and minor
,40 kDa and ,19 kDa species under reducing conditions, as
described previously [23]. In agreement with previous reports,
chromatography confirmed rhGALNS associates as a non-
covalent dimer in solution [23]. The enzyme was stable in serum
with an extrapolated t1/2 of ,200 hrs, at pH=7.4 in vitro.
rhGALNS also exhibited affinity for hydroxyapatite, the major
mineral constituent of bone, comparable to osteopontin, a
hydroxyapatite-binding protein, and arylsulfatase B (ASB), which
Figure 1. rhGALNS production and characterization. A: SDS-PAGE of final purified rhGALNS was stained with Coomassie blue (left) or
immunoblotted for GALNS (right) under reducing conditions. B: Dose-dependent uptake of rhGALNS (0.78 – 25 nM) by primary MPS IVA fibroblasts
(left). Kuptake =2.5 nM was determined by Hanes-Woolf plot linear regression analysis (right). Y axis is reported as [rhGALNS], (nM)/activity (ng/ml),
where rhGALNS is the substrate (of the Mannose-6-phosphate (M6P) receptor), and ng/ml represents ng of active enzyme per ml, based on a
standard reference preparation of purified rhGALNS with specific activity of 2 U/mg. C: M6P inhibited uptake of 2.5 nM GALNS by MPS IVA
fibroblasts. Means of 3 independent experiments are presented.
doi:10.1371/journal.pone.0012194.g001
MPS IVA Model
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dysplasia, MPS VI (Maroteaux-Lamy Syndrome). On the other
hand, a-glucosidase exhibited no affinity to hydroxyapatite
(Figure S1A).
Mannose-6-phosphate (M6P) residues on the oligosaccharides of
lysosomal enzymes are critical to successful ERT, so we evaluated
the structure of the oligosaccharides on rhGALNS. [24]. There are
two consensus N-linked oligosaccharide sites in the polypeptide
sequence of GALNS, Asn204 and Asn423. Mass Spectrometry
analysis revealed that all phosphorylated oligosaccharides reside at
Asn204, consistent with previous reports [25]. rhGALNS
oligosaccharide profile (Figure S1B) indicates phosphorylated
oligosaccharides make up ,50% of the total oligosaccharides.
Therefore, the molar ratio of phosphorylated oligosaccharide to
rhGALNS protein is approximately 1:1, suggesting that each
molecule has the capacity to be taken up by the M6P receptor and
delivered to lysosomes, especially since rhGALNS dimerizes in
solution.
Addition of rhGALNS to MPS IVA fibroblasts corrected their
enzyme deficiency dose-dependently, with a Kuptake of 2.5 nM
(Figure 1B). rhGALNS uptake was M6P receptor-dependent, as
it was significantly inhibited by M6P (Figure 1C).
Primary human MPS IVA chondrocytes as an MPS IVA
model
Murine models lacking active GALNS do not successfully
recapitulate the human skeletal disorder, as unlike the patients,
they do not exhibit skeletal deformities, but do suffer from
substrate accumulation in the brain [26,27,28]. The authors
ascribe this lack of phenotype to the fact that mice do not produce
the same type of skeletal KS as humans [6]. Dermal fibroblasts
from patients are also not optimal since they do not exhibit KS
accumulation nor pathology [12]. Using primary chondrocytes
isolated from iliac crest biopsies of two MPS IVA patients we
established a model of human MPS IVA in vitro. Primary human
chondrocytes, isolated from healthy articular knee cartilage, as
well as MPS IVA chondrocytes supplemented with rhGALNS
were used as controls. Chondrocytes cultured in monolayers de-
differentiate, losing their ability to produce chondrocyte markers,
such as Collagen II and Aggrecan [29]. We maintained chondrocytes
in alginate suspension cultures supplemented with IGF-1, TGFb,
transferrin, insulin and ascorbic acid, conditions which support
chondrocyte differentiation [29,30,31] and extracellular matrix
and KS production in culture [32,33]. We observed chondrogenic
differentiation, hallmarked by synthesis of extracellular matrix
(Figure 2A) and production of major chondrogenic markers
Collagen II and Aggrecan mRNAs (Figure 2B). However, this
approach also slowed cell growth (Figure S2) and limited the
material available for study.
We studied MPS IVA cells during proliferating (monolayers, 6-
week alginate cultures) and differentiated (15 week cultures)
phases. MPS IVA cells retained the fundamental and causative
feature of the MPS IVA phenotype in culture, as they had
undetectable GALNS activity compared to unaffected cells
(Table 1). Lysates of long-term MPS IVA cultures were analyzed
by Capillary Electrophoresis (CE), which revealed an up to 11-fold
increase in KS in MPS IVA cultures, in comparison to unaffected
cells (Figure 2C), indicating KS accumulation.
Although the diffusion-limiting properties of cartilage are not
recapitulated in cultured chondrocytes, the absence of active
rhGALNS and subsequent accumulation of KS, as well as
expression of chondrogenic genes, make MPS IVA chondrocytes
a valuable new model of human MPS IVA in vitro. Translatability
of this model to a clinical context in vivo will become more
apparent with further studies of tissues and cells isolated from MPS
IVA patients.
rhGALNS restores enzyme activity and clears KS in MPS
IVA chondrocytes
We restored GALNS activity in monolayers and alginate
suspension cultures of MPS IVA cells (Table 1). rhGALNS
trafficked to lysosomes, evident by its colocalization with
Lysosomal Associated Membrane Protein-1 (LAMP1) (Figure 3).
Treatment with 1 nM and 10 nM rhGALNS resulted in dose-
dependent uptake of the enzyme in alginate cultures, evident by
immunofluorescence (Figure S3A). The enzyme was taken up
throughout the culture period (Figure S3B).
In order to assess rhGALNS as viable therapy, we addressed its
efficacy in terms of clearing KS accumulation in vitro. Long-term
MPS IVA cultures that exhibited KS accumulation in comparison
to unaffected cells, showed significantly reduced accumulation of
KS (,80 – 100%) when cultured with 1 nM or 10 nM rhGALNS,
in cells from both patients (Figure 4A, B and Figure S4). We did
not observe dose-dependence in these experiments, indicating that
1 nM rhGALNS may be sufficient for restoration of enzyme
activity. KS accumulation was also cleared from mature MPS IVA
cells, which had first accumulated KS for 6 weeks prior to
incubation with rhGALNS (Figure S5). rhGALNS decreased KS
immunofluorescence most significantly in the lysosomal compart-
ment, whereas the immunofluorescence in extracellular matrix was
still visible in treated cells from both patients (Figure 4B and
Figure S4). This observation supports that rhGALNS acts in the
lysosomal compartment, as the therapeutic enzyme is inactive at
extracellular pH and cannot degrade KS without participation of
other lysosomal enzymes. Nevertheless, extracellular KS may also
be affected, secondary to amelioration in KS turnover and
trafficking defects, in response to lysosomal clearance by rhGALNS.
In parallel experiments, superphysiological levels of GALNS in
unaffected chondrocytes incubated with 10 nM rhGALNS did not
result in changes in KS levels (Figure 4A and Figure S6), which
are efficiently metabolized by the endogenously-expressed enzyme.
rhGALNS affects function of MPS IVA cells
Few studies have specifically addressed the effects of KS
accumulation on chondrocyte function and pathophysiology of
MPS IVA. De Franceschi and colleagues recently described
increased expression of Collagen I and decreased expression of
Collagen II and Aggrecan proteins and/or mRNAs in articular
cartilage of patients with Morquio syndrome, in comparison to
unaffected controls [15]. In agreement with the patient findings, we
observed a significantly increased expression of Collagen I in both
proliferating (6 week) and differentiated (11 week) cultures
(Figure 5A) and a decreased expression of Collagen II in
differentiated cultures (Figure 5B). In contrast to articular cartilage
from patients [15], Aggrecan was increased in proliferating MPS IVA
chondrocytes, in comparison to unaffected cells (Figure 5C). It is
possible that the disparate findings in aggrecan expression may
result from age and anatomical differences in tissue sources from
which the cells were isolated. MPS IVA chondrocytes were isolated
from iliac crest growth plates of affected children, whereas control
cells were obtained from articular cartilage of a 70-year old adult.
This is supported by a higher expression of Collagen X, a gene
specifically expressed in growth plate hypertrophic chondrocytes, as
in MPS IVA cells (Figure 5D) [34].
Our results indicate that MPS IVA chondrocytes have
undergone phenotypic changes, secondary to lack of GALNS or
accumulation of KS, which result in aberrant cellular function,
here observed in terms of altered gene expression profile. Bank
MPS IVA Model
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IVA patients process collagen fibrils differently [14]. Altered
expression of Collagen I and II may also indicate a decrease in
chondrocyte differentiation, which is hallmarked by high expres-
sion of collagen II and low expression of collagen I. This
hypothesis is supported by decreased expression of Sox 9
(Figure 5E), a key chondrogenic transcription factor, in
differentiating chondrocytes. Alternatively, the increase in Collagen
Table 1. GALNS activity in MPS IVA cells.
GALNS activity
e
MPS IVA chondrocytes Unaffected chondrocytes
nM rhGALNS: 0 nM 10 nM 0 nM 10 nM
Monolayers, 3 days culture
a ND
c 2.260.18
c 0.160.003 2.260.03
Alginate, 15 weeks culture
b ND
c 1.5
c 0.3 1.6
Alginate, 3 weeks culture
b ND
d 0.8
d 0.21 0.7
ND (none detected) = values ,0.1;
an=3;
bn=1;
cMPS IVA patient 1;
dMPS IVA patient 2.
eEnzyme activity was converted to and reported as ng of active enzyme per ml, based on a standard reference preparation of purified rhGALNS (2 U/mg specific
activity). Activity was normalized per mg of total protein present in the cell lysates.
doi:10.1371/journal.pone.0012194.t001
Figure 2. Primary chondrocytes as a model of MPS IVA in vitro.A :Alcian blue staining of proteoglycans in 6-week cultures. B. Collagen 2
(COL2) and Aggrecan (ACAN) qRT-PCR of RNA isolated from 2-week alginate MPS IVA chondrocyte cultures or monolayers of MPS IVA fibroblast
cultures. Means of triplicates 6SEM are shown (p,0.01 in both graphs). C: Capillary electrophoresis of total cell lysates from 6-week alginate cultures
of MPS IVA cells, digested with keratanase II. Keratan sulfate peaks (Area under the curve; AUC) were normalized for internal control and also protein
content in cell lysates, as cell numbers in MPS IVA cultures were significantly lower than in unaffected controls. Table shows quantification of peaks
expressed as Relative fluorescence units (RFUs)/internal control/mg protein. Experiment was performed in duplicate and representative traces shown.
doi:10.1371/journal.pone.0012194.g002
MPS IVA Model
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compensatory mechanism resulting from Collagen II reduction, as
has been observed in some patients with achondrogenesis type II
[35]. Collagen II is the major structural protein that provides
cartilage with strength and resilience. Its decreased expression has
been associated with ‘‘type II collagenopathies’’, which range in
severity and are hallmarked by dwarfism, skeletal dysplasia,
premature osteoarthritis and hearing loss, similarly to MPS IVA.
The decrease in Collagen II observed in MPS IVA chondrocytes
may therefore result in cartilage properties that engender or
exacerbate dwarfism, as well as spinal deformity, since collagen II
plays a role in formation of nucleus pulposus of the intervertebral
disc [36].
rhGALNS treatment stimulated an increase in production of
key cartilaginous markers, including Sox 9 (differentiated cells,
Figure 5E), Collagen II (Figure 5B), Collagen X (differentiated cells,
Figure 5D) and Aggrecan (proliferating cells, Figure 5C). On the
other hand, abnormal Collagen I expression is decreased by
rhGALNS in differentiated cells (Figure 5A). To our knowledge
this is the first report to describe corrective effect of rhGALNS on
function of human MPS IVA chondrocytes. Altered expression of
major cartilaginous ECM proteins could lead to alteration in the
biomechanical properties of the tissue. ECM perturbations in
articular cartilage from two MPS IVA patients were recently
characterized by Bank et al, who proposed the altered collagen
fibrils and proteoglycan arrangements result in cartilage more
Figure 3. rhGALNS is internalized into lysosomes of MPS IVA chondrocytes. Chondrocytes treated with 10 nM rhGALNS for 3 days
exhibited GALNS staining (green), which colocalized (orange) with a lysosomal marker, LAMP1 (red). Confocal images were acquired with identical
parameters.
doi:10.1371/journal.pone.0012194.g003
MPS IVA Model
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expression in MPS IVA patients by rhGALNS treatment may
therefore lead to improvement of biomechanical properties of
cartilage resulting in improved joint health and spinal deformities.
rhGALNS is taken up by therapeutically-relevant tissues
in vivo
In the present study we studied enzyme biodistribution
particularly focusing on clinically-relevant cartilage, heart valve
and macrophages, in wild-type mice after multiple enzyme
administrations. To avoid non-specific signal associated with
antibody detection techniques, we directly visualized exogenously-
applied enzyme, by detecting the conjugated Alexa-488 fluor-
ophore. Cellular uptake and subcellular localization of the enzyme
was not affected by the fluorophore conjugation (Figure S7),
making rhGALNS-A488 a suitable tool to study rhGALNS tissue
biodistribution in vivo. Nonetheless, as one fluorophore represented
one monomer of rhGALNS, this method may have resulted in
enzyme underestimation.
Delivery of therapeutic enzymes to growth plate chondrocytes
is exacerbated by the avascular nature of cartilage [16]. This is
also true for the deep layers of the heart valve, which are rich in
glycosaminoglycans, but are not well vascularized [17]. Tomatsu
and colleagues have shown that a single administration of
enzyme does not result in significant delivery to the growth plate
[37]. Chronic treatment of GALNS-null mice on the other hand
did result in increased enzyme activity in preparations of whole
bones, although these studies did not specifically address enzyme
biodistribution in cartilage [38,39]. In these studies Tomatsu
and colleagues proposed that rhGALNS tagged with an N-
terminus hexaglutamate sequence (E6-GALNS) would target
mineralized bone, which contains high amounts of hydroxyap-
atite. Nevertheless, a study showing delivery of the therapeutic
enzyme to the non-mineralized cartilage is still outstanding. We
here present the first report of rhGALNS biodistribution
specifically in the mouse growth plate and articular cartilage,
indicating that non-tagged rhGALNS successfully diffuses
through the avascular cartilage to reach chondrocytes, the
primary target cells.
Repeat injections of rhGALNS-A488 in mice resulted in
enzyme delivery throughout growth plate and articular cartilage
(Figure 6A, D). Notably, rhGALNS-A488 fluorescence was
present throughout the growth plate, albeit in a gradient fashion,
with the highest abundance at the cartilage/bone interface, in
resting and hypertrophic chondrocytes. Such biodistribution may
be a reflection of the proximity of these cells to the vasculature
present in the neighboring bone. In favor of this hypothesis is the
finding of significant enzyme delivery in the well-vascularized bone
marrow (Figure 6A, D). Our results demonstrate that rhGALNS
is compatible with diffusion through proteoglycan-rich matrices,
indicating that increasing the concentration and/or duration of
Figure 4. rhGALNS clears KS accumulation from MPS IVA chondrocytes. A: Capillary electrophoresis of keratanase II-digested total cell
lysates from 6-week alginate cultures treated with rhGALNS continuously. Keratan sulfate peaks (Area under the curve; AUC) were normalized for
internal control and also protein content in cell lysates, as cell numbers in MPS IVA cultures were significantly lower than in unaffected controls. Table
shows quantification of peaks expressed as Relative fluorescence units (RFUs)/internal control/mg protein.
1n=1 is shown as the second sample had
undetectable peaks. Experiment was performed in duplicate and representative traces shown. Green = MPS IVA chondrocytes; Blue = MPS IVA
chondrocytes treated with 1 nM rhGALNS; Red = bovine corneal KS standard. Arrows: disaccharide peaks Gal6S-GlcNAc6S and Gal-GlcNAc6S.
Asterisk: GlcNAc6S internal control. B: KS immunofluorescence in MPS IVA chondrocytes from patient 2 after continuous treatment with rhGALNS.
Fresh enzyme was added to culture medium twice a week for 6 weeks. Arrowheads = extracellular KS; Arrows = intracellular KS. Images were
acquired with identical parameters. KS = green, LAMP1 = red, colocalization = orange.
doi:10.1371/journal.pone.0012194.g004
MPS IVA Model
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improvements in biodistribution.
KS accumulates in the heart valve of MPS IVA patients, and
represents a cause of morbidity in this disease [40]. We observed
rhGALNS-A488 in the septum, atrium, and heart valve, and we
focused on the heart valve for volumetric analysis. Although the
heart valve is poorly vascularized [17], we observed significant
penetration of rhGALNS-A488, past the endothelium and
throughout the valve (Figure 6B). Interestingly, enzyme pene-
tration in the heart valve was significantly higher than in growth
plate (Figure 6D). Lysosomal localization of rhGALNS-A488 is
shown in Figure 6B.
MPS IVA patients experience accumulation of skeletal KS in
the liver [41,42] and some experience hepatomegaly [43]. Our
studies revealed significant rhGALNS-A488 delivery in the
sinusoidal cells and macrophages of the liver (Kuppfer cells)
(Figure 7A). Correction of enzyme levels and clearance of KS
accumulation in macrophages may have important clinical
implications, as these cells are significantly affected in multiple
MPS disorders [44], including MPS IVA [4,5], and as such are
contributing to inflammation and tissue dysfunction. In another
MPS disorder, Gaucher disease, ERT resulted in increased
macrophage function leading to hematologic and splenohepatic
improvements [45]. Confocal microscopy at high magnification
revealed enzyme uptake by albumin-positive hepatocytes
(Figure 7B). Enzyme uptake in liver was higher than other
tissues examined (Figure 7C).
Summary
rhGALNS has the potential to reach clinically relevant tissues,
including cartilage, heart valve and macrophages, to be taken into
lysosomes, by M6P receptors, and to clear accumulated KS,
thereby potentially preventing the progression of MPS IVA
disease. Amelioration of aberrant gene expression by rhGALNS
suggests that enzyme replacement therapy may have an effect on
pathophysiology that goes beyond reducing lysosomal storage, and
results in restoration of normal cellular physiology.
Methods
Mice
Female 4–5 week-old weight-matched Balb/c mice were used
for experiments in accordance with the Institutional Animal Care
and Use Committee of the Buck Institute for Age Research,
protocol number 10150.
Production and purification of rhGALNS
cDNAs for human GALNS and SUMF-1, each subcloned into a
eukaryotic expression vector pCDNA4 containing the Zeocin
resistance marker (Invitrogen), were transfected into CHO cells.
After establishing a stable pool in Zeocin-containing medium,
individual clones were selected by limited dilution. Clones were
expanded and adapted to suspension cultures in production medium
(Ex-Cell 302, JRH Biosciences). Cell culture fluid containing
rhGALNS was filtered, concentrated ,20-fold and diafiltered into
Figure 5. Gene expression changes in MPS IVA chondrocytes after rhGALNS treatment. cDNAs were generated from RNA from 6-week
cultures (patient 1) and 11-week cultures (patient 1 and patient 2) of chondrocytes. Cells were either grown in absence (white bars) or presence of
10 nM GALNS (grey bars). Chondrocytes were supplemented with 10 nM rhGALNS throughout culture (6-week cultures) or for the last 5 weeks of
culture (11-week cultures). Fresh enzyme was added to culture medium twice a week. Results from unaffected articular adult chondrocytes cells are
shown (black bars). Results were normalized for GAPDH expression and shown as means of triplicates 6SEM for patient 1 (6 week cultures) or patient
1 and patient 2 (11-week cultures).
doi:10.1371/journal.pone.0012194.g005
MPS IVA Model
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onto an ion-exchange column. Protein impurities were removed on
an IMAC and a hydrophobic interaction chromatography column.
The eluate was concentrated and diafiltered into the formulation
buffer. Enzyme purity was ascertained by SDS-PAGE (4–12%) and
reverse-phase HPLC methods. Total protein concentrations were
determined by Bradford protein assay.
rhGALNS ELISA and capture activity assay
For quantification of total rhGALNS, molecules were captured
by polyclonal GALNS antibodies (BioMarin) and incubated with
an rhGALNS antibody conjugated to HRP (BioMarin). Tetra-
methylbenzidine substrate induced a colorimetric reaction mea-
sured at 450 nm. Activity of rhGALNS was determined by
modification of a published method [46]. Briefly, rhGALNS
molecules, captured by polyclonal GALNS antibodies (5 mg/ml),
desulfated 1 mM 4-methylumbelliferyl-galactoside 6-sulphate
(4MU-Gal-6S) in 25 mM sodium acetate, pH 4.0 containing
1 mM NaCl (37uC, 30 min). Subsequent reaction with 25 mg/ml
b-galactosidase (in 300 mM NaPi pH 7.2, 37uC, 15 min) cleaved
the fluorescent molecule 4MU which was quantified by excitation
at 355 nm, emission at 460 nm. Amounts of rhGALNS in the
samples were extrapolated from a standard curve with known
concentrations of rhGALNS. Activity of 1U was defined as
production of 1 mmole of 4-MU/min at 37uC and pH 4. Activity
was converted to and reported as ng of active enzyme per ml,
based on a standard reference preparation of purified rhGALNS
with specific activity of 2 U/mg. This result was then normalized
per mg of total protein present in the cell lysates.
Coomassie staining and immunoblotting
Proteins were separated by a reducing SDS-PAGE and stained
with Coomassie blue or electroblotted to nitrocellulose membranes
for immunoblotting. rhGALNS was detected with anti-rhGALNS
antibodies (1:5,000; BioMarin), and alkaline phosphatase-conju-
gated secondary antibodies (1:5,000; Promega). Immunoblots were
developed with Western BlueTM substrate (Promega).
rhGALNS fluorophore labeling
rhGALNS was labeled with Alexa Fluor 488 (A-488; Invitrogen)
by maleimide chemistry. The overall charge of labeled rhGALNS
Figure 6. rhGALNS biodistribution in wild-type mouse cartilage, bone marrow and heart valve. A: Confocal microscopy of direct
rhGALNS-A488 fluorescence in growth plate cartilage, articular cartilage and bone marrow cells (green). Blue = DAPI nuclear staining. Original
magnification 80x. B: rhGALNS-A488 (green) biodistribution throughout the heart valve and colocalization (orange) with lysosomal marker LAMP1
(red). Control section from a mouse treated with the fluorophore A-488/PBS alone is shown. Original magnification 40x. C: Confocal stacks are
analyzed for fluorescence intensity and data presented as average fluorescent signal (RFU)/mm
3. Measurements of sections from mice that were either
injected with A-488/PBS (0), or rhGALNS-A488 and sacrificed at 2 hr (2), 4 hr (4), or 8 hr (8) after injection (n=3). Means 6SEM are shown.
doi:10.1371/journal.pone.0012194.g006
MPS IVA Model
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absorbance spectroscopy and was always greater than 90% (1:1,
fluorophore:GALNS).
rhGALNS uptake experiments in vitro
Primary human MPS IVA fibroblasts (GM593 cells; Human
Genetic Mutant Cell Repository; Camden, NJ) were main-
tained in DMEM medium supplemented with 10% fetal bovine
s e r u m ,1m Mp y r u v a t ea n d2m ML -glutamine. Normal rabbit
synoviocytes (CRL-1832; ATCC) were cultured in Ham’s F12
medium, supplemented with 10% fetal bovine serum and
antibiotics (Penicillin and Streptomycin). In a modified pulse-
chase experiment, confluent cells were incubated with
rhGALNS and/or rhGALNS-A488 (4 hr, pulse), followed by
rhIduronidase (2 hr, chase). Cells were lysed in M-PER
(Pierce). rhGALNS in cell lysates was quantified by GALNS
ELISA. For mannose-6-phosphate (M6P) competition experi-
ment, fibroblasts were incubated in 2.5 nM rhGALNS in the
presence of increasing concentrations of M6P (12.5 mM–
0.4 mM).
Primary human MPS IVA chondrocytes
Primary human chondrocytes isolated from iliac crest biopsies
of two patients with MPS IVA were a gift from Dr. Wilcox
(Cedars-Sinai Medical Center, Los Angeles, CA). Unaffected
normal human knee chondrocytes were obtained from Lonza
(Walkersville, MD). Chondrocyte monolayers were cultured in
proliferation medium (CGM, Lonza) and were lysed with M-PER
(Pierce) with protease inhibitors (Roche Diagnostics, Manheim,
Germany) for determination of rhGALNS activity, or were fixed
with 4% paraformaldehyde for immunocytochemistry. Alginate
suspension cultures were established [31] and maintained in
differentiation medium (CDM, Lonza) and ascorbic acid
(100 mg/ml). Weekly samples of alginate beads were taken for
histology, immunocytochemistry and estimation of proliferation.
For immunocytochemistry, beads were depolymerized in 55 mM
Sodium Citrate (Sigma), trypsinized, adhered to salinized slides
(Sigma) by centrifugation (2500 RMP, 20 min) and fixed in
acetone (5 min). Upon completion of the study, the beads were
depolymerized and pelleted as above, then lysed in M-PER with
protease inhibitors (Sigma). Total protein content was quantified
(NanoDrop).
Extracellular matrix staining
Beads were fixed in 4% PFA, dehydrated, embedded in paraffin
and sectioned (5 mm). Sections were stained in Alcian blue
(30 min) and counterstained in hematoxylin for brighfield
microscopy.
Immunocytochemistry
Cells were permeabilized (0.25% Triton/PBS; 5 min) and
blocked (10% Normal Goat Serum; 30 min). Primary antibodies,
polyclonal anti-GALNS (1 mg/ml), polyclonal anti-GALNS cova-
lently conjugated with Alexa-488 fluorophore, monoclonal anti-
KS (1:200; Chemicon International) and monoclonal or polyclonal
anti-LAMP1 antibodies (1:200; Santa Cruz Biotechnology) were
applied 30 min at RT or ON at 4uC. Goat secondary antibodies
(1:200; Invitrogen) were applied for 30 min. In case of synovio-
cytes this step was omitted. Slides were mounted in ProlongGold
with DAPI (Invitrogen).
Quantitative RT-PCR (qPCR)
Chondrocyte RNA was extracted (RNeasy Plus Mini Kit,
Qiagen) and used to generate cDNAs (High capacity RNA-to-
cDNA kit; Applied Biosystems). Gene expression was quantified
using probe-based TaqMan q-PCR assays (Applied Biosystems)
and the LightCycler 480 Real-Time PCR System (Roche). A
crossing point (CP) determined for each gene of interest, using a
Second Derivative Maximum Method, was normalized to the
mean CP for Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) in the same sample.
Figure 7. rhGALNS biodistribution in wild-type mouse liver. A: Confocal microscopy of direct rhGALNS-A488 fluorescence in liver (green)
reveals significant uptake of enzyme into macrophages (Kupffer cells). Blue = DAPI nuclear staining. Original magnification 406 B: High power
confocal microscopy shows uptake of rhGALNS-A488 by hepatocytes by direct fluorescence alone (upper panel) and after staining hepatocytes for
albumin (red, lower panel). Original magnification 636with 5.76zoom. C: Confocal stacks at 406were analyzed for fluorescence intensity and data
presented as average fluorescent signal (RFU)/mm
3. Measurements of sections from mice that were either injected with A-488/PBS (0), or rhGALNS-
A488 and sacrificed at 2 hr (2), 4 hr (4), or 8 hr (8) after injection (n=3). Means 6SEM are shown.
doi:10.1371/journal.pone.0012194.g007
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Electrophoresis (CE)
Cell lysates were digested with keratanase II, producing
disaccharides from KS. The disaccharides were derivatized by
reductive amination with the fluorescent dye 2-Aminoacridone,
and measured by the P/ACE MDQ CE (BeckmanCoulter) using
Laser Induced Fluorescence (LIF), with the laser excitation
wavelength at 488 nm. The assay measured KS independently
of its molecular size or processing state.
Biodistribution of rhGALNS-A488
Five bolus administrations of 10 mg/kg rhGALNS-A488
(n=3/group), PBS/Cys-A488 (n=2/group) or PBS (n=1/
group), were injected in the tail vein every two days. Heart, liver,
femurs and tibias were dissected 2 hr (rhGALNS-A488, PBS/Cys-
A488, PBS), 4 hr (rhGALNS-A488) and 8 hr (rhGALNS-A488,
PBS/Cys-A488, PBS) after the last treatment. Tissues were fixed
in 4% PFA, dehydrated, paraffin embedded and sectioned at
7 mM. Bones were decalcified in 10% Formic Acid/PBS until no
calcium oxalate precipitate formed with 5% ammonium oxalate.
Sections were deparaffinized and rehydrated prior to antigen
retrieval in 10 mM citrate (30 min, 80uC), then blocked (1%
normal donkey serum, 0.1% bovine serum albumin, 0.1% NaN3,
0.3% Triton X-100 in PBS; 1 hr; RT) and incubated in polyclonal
GALNS antibodies, polyclonal mouse albumin antibodies (Abcam)
or monoclonal LAMP-1 antibody (4uC, ON). Secondary donkey
anti-mouse or rabbit antibodies, conjugated to Alexa-555 were
applied (1 hr, RT; Invitrogen). Sections were mounted in ProLong
Gold with DAPI. For quantification of signal intensity, confocal
stacks were acquired using a Zeiss LSM 510 NLO with a 406
objective, 26zoom and 0.53 mm z increment.
Supporting Information
Figure S1 rhGALNS characterization. A: GALNS exhibited
affinity to hydroxyapatite, comparable to osteopontin (R&D
systems) and arylsulfatase B (ASB; BioMarin). a- glucosidase
(BioMarin) exhibited no affinity to hydroxyapatite. Affinities to
100 mg hydroxyapatite, in the presence of 50 mg/ml of BSA were
determined by HPLC. B: The oligosaccharide profile of GALNS
was generated by PNGF digestion, followed by APTS labeling and
CE. Oligosaccharide peaks 1-5 are phosphorylated oligomannose
and constitute 50% of the total profile.
Found at: doi:10.1371/journal.pone.0012194.s001 (0.28 MB TIF)
Figure S2 Chondrocyte proliferation. Cells released from
alginate cultures were permeabilized in 0.25% Triton/PBS
(5 min) and stained with DAPI (Invitrogen). Nuclei of 45 cell
aggregates ($3 cells) were counted. Cell numbers were quantified
by counting nuclei in 45 cell aggregates per sample. Mean cell
numbers 6SEM per cell aggregate are shown. Photomicrographs
of an individual clonal aggregate of unaffected and MPS IVA cells
in alginate cultures are shown.
Found at: doi:10.1371/journal.pone.0012194.s002 (0.34 MB TIF)
Figure S3 GALNS uptake by chondrocytes in alginate. A: MPS
IVA chondrocytes were grown for 6 weeks in the presence of
1 nM and 10 nM rhGALNS. B: MPS IVA chondrocytes were
grown for 6 weeks, then incubated with 10 nM rhGALNS for
additional 9 weeks. GALNS= green, LAMP1= red). All images
were acquired with identical parameters.
Found at: doi:10.1371/journal.pone.0012194.s003 (5.32 MB TIF)
Figure S4 KS immunofluorescence in MPS IVA chondrocytes
from patient 1. Cells were incubated with 10 nM rhGALNS for 6
weeks (terminal time point shown) in alginate suspension cultures.
Images were acquired with identical parameters. KS = green,
LAMP1 = red. Arrowheads = extracellular KS; Arrows =
intracellular KS.
Found at: doi:10.1371/journal.pone.0012194.s004 (4.95 MB TIF)
Figure S5 Capillary electrophoresis (CE) of keratanase II-
digested MPS IVA chondrocyte lysates. MPS IVA chondrocytes
were grown for 6 weeks, then incubated with 10 nM rhGALNS
for additional 9 weeks. Green = MPS IVA chondrocytes;
Yellow= MPS IVA chondrocytes treated with 1 nM rhGALNS;
Red = bovine corneal KS standard. Arrows: disaccharide peaks
Gal6S-GlcNAc6S and Gal-GlcNAc6S. Asterisk: GlcNAc6S inter-
nal control.
Found at: doi:10.1371/journal.pone.0012194.s005 (0.46 MB TIF)
Figure S6 GALNS uptake and KS immunofluorescence in
unaffected chondrocytes. Unaffected chondrocytes were grown for
6 weeks in the presence 10 nM rhGALNS in alginate suspension
cultures. Images were acquired with identical parameters. A:
GALNS = green, LAMP1 = red. B: KS = green, LAMP1 =
red.
Found at: doi:10.1371/journal.pone.0012194.s006 (2.85 MB TIF)
Figure S7 Visualization of rhGALNS. A: Rabbit synoviocytes
exhibit comparable uptake of rhGALNS and rhGALNS-A488 by
GALNS ELISA. B: Comparison of direct (rhGALNS-A488, green,
left panel) and amplified indirect (anti-GALNS antibodies,
secondary antibodies conjugated to A555, red, right panel)
detection of GALNS in rabbit synoviocytes treated with rhGALNS
(10 nM, 4 hrs). Arrows show examples of points of equivalent
signal distribution.
Found at: doi:10.1371/journal.pone.0012194.s007 (0.71 MB TIF)
Acknowledgments
We would like to gratefully acknowledge Dr. William Wilcox (Cedar-Sinai
Hospital, LA) for the gift of MPS IVA chondrocytes.
Author Contributions
Conceived and designed the experiments: MMDE DW CH TC VK MV.
Performed the experiments: MMDE DW CH TC VK DC. Analyzed the
data: MMDE DW CH TC VK. Contributed reagents/materials/analysis
tools: MMDE DW. Wrote the paper: MMDE DW CH VK DC EK MV.
References
1. Northover H, Cowie RA, Wraith JE (1996) Mucopolysaccharidosis type IVA
(Morquio syndrome): a clinical review. J Inherit Metab Dis 19: 357–365.
2. Neufeld E, Muenzer J (1995) The mucopolysaccharidoses. In: CR S, AL B,
WS S, D V, eds. The Metabolic and Molecular Basis of Inherited Disease. 7 ed.
New York: McGraw-Hill.
3. Grande-Allen KJ, Calabro A, Gupta V, Wight TN, Hascall VC, et al. (2004)
Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and
chordae: association with regions of tensile and compressive loading.
Glycobiology 14: 621–633.
4. Vogler C, Rosenberg HS, Williams JC, Butler I (1987) Electron microscopy in
the diagnosis of lysosomal storage diseases. Am J Med Genet Suppl 3: 243–255.
5. Factor SM, Biempica L, Goldfischer S (1978) Coronary intimal sclerosis in
Morquio’s syndrome. Virchows Arch A Pathol Anat Histol 379: 1–10.
6. Montano AM, Goldim M, Satta Y, Takahata N, Tomatsu S. Implications of
absence of clinical phenotype on Morquio A mice: Why rodents do not require
skeletal keratan sulfate? 2008 November 12th; Philadelphia, Pennsylvania.
7. Beck M (2001) Variable clinical presentation in lysosomal storage disorders.
J Inherit Metab Dis 24 Suppl 2: 47–51; discussion 45–46.
MPS IVA Model
PLoS ONE | www.plosone.org 10 August 2010 | Volume 5 | Issue 8 | e121948. Stevens JM, Kendall BE, Crockard HA, Ransford A (1991) The odontoid
process in Morquio-Brailsford’s disease. The effects of occipitocervical fusion.
J Bone Joint Surg Br 73: 851–858.
9. Dangel JH (1998) Cardiovascular changes in children with mucopolysaccharide
storage diseases and related disorders–clinical and echocardiographic findings in
64 patients. Eur J Pediatr 157: 534–538.
10. Anderson CE, Crane JT, Harper HA, Hunter TW (1962) Morquio’s disease and
dysplasia epiphysalis multiplex. A study of epiphyseal cartilage in seven cases.
J Bone Joint Surg Am 44-A: 295–306.
11. McClure J, Smith PS, Sorby-Adams G, Hopwood J (1986) The histological and
ultrastructural features of the epiphyseal plate in Morquio type A syndrome
(mucopolysaccharidosis type IVA). Pathology 18: 217–221.
12. Hollister DW, Cohen AH, Rimoin DL, Silberberg R (1975) The Morquio
syndrome (mucopolysaccharidosis IV): Morphologic and biochemical studies.
Johns Hopkins Med J 137: 176–183.
13. Engfeldt B, Hjerpe A, Mengarelli S, Reinholt FP, Wikstrom B (1982)
Morphological and biochemical analysis of biopsy specimens in disorders of
skeletal development. Acta Paediatr Scand 71: 353–363.
14. Bank RA, Groener JE, van Gemund JJ, Maaswinkel PD, Hoeben KA, et al.
(2009) Deficiency in N-acetylgalactosamine-6-sulfate sulfatase results in collagen
perturbations in cartilage of Morquio syndrome A patients. Mol Genet Metab
97: 196–201.
15. De Franceschi L, Roseti L, Desando G, Facchini A, Grigolo B (2007) A
molecular and histological characterization of cartilage from patients with
Morquio syndrome. Osteoarthritis Cartilage 15: 1311–1317.
16. Shim SS, Leung G (1986) Blood supply of the knee joint. A microangiographic
study in children and adults. Clin Orthop Relat Res. pp 119–125.
17. Hammon JW Jr, O’Sullivan MJ, Oury J, Fosburg RG (1974) Allograft cardiac
valves. A view through the scanning electron microscope. J Thorac Cardiovasc
Surg 68: 352–360.
18. Peters C, Steward CG (2003) Hematopoietic cell transplantation for inherited
metabolic diseases: an overview of outcomes and practice guidelines. Bone
Marrow Transplant 31: 229–239.
19. Kakkis ED (2002) Enzyme replacement therapy for the mucopolysaccharide
storage disorders. Expert Opin Investig Drugs 11: 675–685.
20. Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, et al. (2003) The
multiple sulfatase deficiency gene encodes an essential and limiting factor for the
activity of sulfatases. Cell 113: 445–456.
21. Landgrebe J, Dierks T, Schmidt B, von Figura K (2003) The human SUMF1
gene, required for posttranslational sulfatase modification, defines a new gene
family which is conserved from pro- to eukaryotes. Gene 316: 47–56.
22. Fraldi A, Biffi A, Lombardi A, Visigalli I, Pepe S, et al. (2007) SUMF1 enhances
sulfatase activities in vivo in five sulfatase deficiencies. Biochem J 403: 305–312.
23. Masue M, Sukegawa K, Orii T, Hashimoto T (1991) N-acetylgalactosamine-6-
sulfate sulfatase in human placenta: purification and characteristics. J Biochem
110: 965–970.
24. Dahms NM, Lobel P, Kornfeld S (1989) Mannose 6-phosphate receptors and
lysosomal enzyme targeting. J Biol Chem 264: 12115–12118.
25. Bielicki J, Fuller M, Guo XH, Morris CP, Hopewood JJ, et al. (1995) Expression,
purification and characterization of recombinant human N-acetylgalactosamine-
6-sulphatase. Biochem J 311(Pt 1): 333–339.
26. Tomatsu S, Orii KO, Vogler C, Nakayama J, Levy B, et al. (2003) Mouse model
of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by
targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet
12: 3349–3358.
27. Tomatsu S, Gutierrez M, Nishioka T, Yamada M, Tosaka Y, et al. (2005)
Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to
human N-acetylgalactosamine-6-sulfate sulfatase. Hum Mol Genet 14:
3321–3335.
28. Tomatsu S, Vogler C, Montano AM, Gutierrez M, Oikawa H, et al. (2007)
Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the
active site cysteine conserved among sulfatase proteins. Mol Genet Metab 91:
251–258.
29. Gosset M, Berenbaum F, Thirion S, Jacques C (2008) Primary culture and
phenotyping of murine chondrocytes. Nat Protoc 3: 1253–1260.
30. Elima K, Vuorio E (1989) Expression of mRNAs for collagens and other matrix
components in dedifferentiating and redifferentiating human chondrocytes in
culture. FEBS Lett 258: 195–198.
31. Gagne TA, Chappell-Afonso K, Johnson JL, McPherson JM, Oldham CA, et al.
(2000) Enhanced proliferation and differentiation of human articular chondro-
cytes when seeded at low cell densities in alginate in vitro. J Orthop Res 18:
882–890.
32. Melching LI, Roughley PJ (1999) Modulation of keratan sulfate synthesis on
lumican by the action of cytokines on human articular chondrocytes. Matrix Biol
18: 381–390.
33. Funderburgh ML, Mann MM, Funderburgh JL (2008) Keratocyte phenotype is
enhanced in the absence of attachment to the substratum. Mol Vis 14: 308–317.
34. Goldring MB (2006) Update on the biology of the chondrocyte and new
approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 20:
1003–1025.
35. Chan D, Cole WG, Chow CW, Mundlos S, Bateman JF (1995) A COL2A1
mutation in achondrogenesis type II results in the replacement of type II
collagen by type I and III collagens in cartilage. J Biol Chem 270: 1747–1753.
36. Mundlos S, Olsen BR (1997) Heritable diseases of the skeleton. Part II:
Molecular insights into skeletal development-matrix components and their
homeostasis. FASEB J 11: 227–233.
37. Tomatsu S, Montano AM, Gutierrez M, Grubb JH, Oikawa H, et al. (2007)
Characterization and pharmacokinetic study of recombinant human N-
acetylgalactosamine-6-sulfate sulfatase. Mol Genet Metab 91: 69–78.
38. Tomatsu S, Montano AM, Ohashi A, Gutierrez MA, Oikawa H, et al. (2008)
Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum
Mol Genet 17: 815–824.
39. Tomatsu S, Montano AM, Dung VC, Ohashi A, Oikawa H, et al. Enhancement
of Drug Delivery: Enzyme-replacement Therapy for Murine Morquio A
Syndrome. Mol Ther.
40. John RM, Hunter D, Swanton RH (1990) Echocardiographic abnormalities in
type IV mucopolysaccharidosis. Arch Dis Child 65: 746–749.
41. Minami R, Abo K, Kudoh T, Tsugawa S, Oyanagi K, et al. (1979) Identification
of keratan sulfate in liver affected by Morquio syndrome. Clin Chim Acta 93:
207–213.
42. Minami R, Ikeno T, Igarashi C, Tsugawa S, Nakao T (1983) Characterization of
keratan sulfate isolated from liver affected by Morquio syndrome. Tohoku J Exp
Med 139: 321–326.
43. Montano AM, Tomatsu S, Gottesman GS, Smith M, Orii T (2007)
International Morquio A Registry: clinical manifestation and natural course of
Morquio A disease. J Inherit Metab Dis 30: 165–174.
44. Castaneda JA, Lim MJ, Cooper JD, Pearce DA (2008) Immune system
irregularities in lysosomal storage disorders. Acta Neuropathol 115: 159–174.
45. Marodi L, Kaposzta R, Toth J, Laszlo A (1995) Impaired microbicidal capacity
of mononuclear phagocytes from patients with type I Gaucher disease: partial
correction by enzyme replacement therapy. Blood 86: 4645–4649.
46. van Diggelen OP, Zhao H, Kleijer WJ, Janse HC, Poorthuis BJ, et al. (1990) A
fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV
A). Clin Chim Acta 187: 131–139.
MPS IVA Model
PLoS ONE | www.plosone.org 11 August 2010 | Volume 5 | Issue 8 | e12194